Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
预测基底样三阴性乳腺癌新辅助化疗方案(Durvalumab联合白蛋白紫杉醇和高剂量多柔比星/环磷酰胺)疗效的标志物
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-21-3215
Blenman, Kim R M; Marczyk, Michal; Karn, Thomas; Qing, Tao; Li, Xiaotong; Gunasekharan, Vignesh; Yaghoobi, Vesal; Bai, Yalai; Ibrahim, Eiman Y; Park, Tristen; Silber, Andrea; Wolf, Denise M; Reisenbichler, Emily; Denkert, Carsten; Sinn, Bruno V; Rozenblit, Mariya; Foldi, Julia; Rimm, David L; Loibl, Sibylle; Pusztai, Lajos